Literature DB >> 6243359

Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.

L L Simpson.   

Abstract

Botulinum toxin-induced paralysis of neuromuscular transmission involves at least three steps. There is an initial binding step that is nontoxic, a translocation step that is nontoxic and a subsequent lytic step that produces blockade of transmission. In the absence of nerve stimulation, the binding step has a half-time of similar to or approximately 12 min and a rate constant of similar to or approximately 0.058 . min-1. The binding step does not require calcium or nerve stimulation, and it has a low temperature dependence (Q10 similar to or approximately 1.6). In the absence of nerve stimulation, the translocation step has a half-time of similar to or approximately 4.9 min and a rate constant of similar to or approximately 0.141 . min-1. Translocation requires physiological concentrations of calcium. In the virtual absence of nerve stimulation (1 x 10(-2) Hz), the lytic step has a half-time of similar to or approximately 55 min and a rate constant of similar to or approximately 0.013 . min-1. The lytic step requires calcium, is facillitated by nerve stimulation and has a high temperature dependence by nerve stimulation and has a high temperature dependence (Q10 similar to or approximately 4.2). These data are used to propose a model for botulinum toxin interaction with the cholinergic nerve terminal.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243359

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  70 in total

Review 1.  The use of botulinum toxin for the treatment of gastrointestinal motility disorders.

Authors:  Frank Friedenberg; Satya Gollamudi; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 2.  Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques.

Authors:  A S Schroeder; S Berweck; S H Lee; F Heinen
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin.

Authors:  S Kozaki; Y Kamata; T Nagai; J Ogasawara; G Sakaguchi
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

Review 4.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

5.  Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.

Authors:  F Chen; G M Kuziemko; R C Stevens
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.

Authors:  F Chen; G M Kuziemko; P Amersdorfer; C Wong; J D Marks; R C Stevens
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 7.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

8.  The Use of Botulinum Toxins for Chronic Pain and Headaches.

Authors:  Charles E. Argoff
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

9.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

10.  Insights into the evolutionary origins of clostridial neurotoxins from analysis of the Clostridium botulinum strain A neurotoxin gene cluster.

Authors:  Andrew C Doxey; Michael D J Lynch; Kirsten M Müller; Elizabeth M Meiering; Brendan J McConkey
Journal:  BMC Evol Biol       Date:  2008-11-14       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.